Novartis Settlement Encompasses Whistleblower Claims Of Kickbacks For Diovan Prescribing
This article was originally published in The Pink Sheet Daily
Executive Summary
The company agrees to pay $422.5 million to resolve civil and criminal claims related to off-label use and kickbacks, including allegations that it paid doctors' speaking and consulting fees based upon the volume of prescriptions they wrote for its hypertension drugs.